These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The efficacy of parenteral gold after auranofin failure in rheumatoid arthritis. Wessel J; Davis P J Rheumatol; 1983 Aug; 10(4):664. PubMed ID: 6413690 [No Abstract] [Full Text] [Related]
4. Auranofin: more than just oral gold. Waller ES Clin Pharm; 1984; 3(2):195. PubMed ID: 6426845 [No Abstract] [Full Text] [Related]
5. [Basic therapy of rheumatoid arthritis with auranofin]. Goebel KM Dtsch Med Wochenschr; 1985 Jan; 110(2):64-5. PubMed ID: 3917898 [No Abstract] [Full Text] [Related]
6. Treatment with auranofin in patients with rheumatoid arthritis, previously experiencing drug related side effects to sodium aurothiomalate. Davis P; Landon M J Rheumatol; 1985 Jun; 12(3):622. PubMed ID: 3930724 [No Abstract] [Full Text] [Related]
11. [Evaluation of lymphocyte subpopulations using monoclonal antibodies in patients with rheumatoid arthritis undergoing treatment with a new gold salt (auranofin)]. Di Matteo L; D'Incecco V; Evangelista L; Castiglione C; Consoli G Boll Soc Ital Biol Sper; 1985 May; 61(5):777-81. PubMed ID: 3927943 [No Abstract] [Full Text] [Related]
12. Auranofin in the treatment of rheumatoid arthritis. A two-year study. Baldassare AR; Weiss TD; Arthur RE; Osborn TG; Moore TL; Zuckner J Mo Med; 1985 Nov; 82(11):711-5. PubMed ID: 3934512 [No Abstract] [Full Text] [Related]
13. Gold in rheumatoid arthritis; the past, present and future. Proceedings of a symposium held in Copenhagen, April 15-16, 1983. Scand J Rheumatol Suppl; 1983; 51():1-139. PubMed ID: 6426042 [No Abstract] [Full Text] [Related]
14. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts]. Chamouard JM; Clerc D; Bisson M; Medicis P; Massias P Rev Rhum Mal Osteoartic; 1985 Apr; 52(4):277-82. PubMed ID: 3923604 [No Abstract] [Full Text] [Related]
15. Auranofin treatment for adult rheumatoid arthritis. Comparison of 2 mg and 6 mg daily dose. Bernhard GC J Rheumatol Suppl; 1982; 8():149-53. PubMed ID: 6813477 [TBL] [Abstract][Full Text] [Related]
16. [Preliminary results of oral gold treatment with auranofin following lack of success of intramuscular gold therapy]. Rainer F; Ulreich A Wien Klin Wochenschr Suppl; 1984; 156():49-51. PubMed ID: 6442058 [No Abstract] [Full Text] [Related]
17. Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients. Walz DT; Griswold DE; DiMartino MJ; Bumbier EE J Rheumatol; 1981; 8(5):829-32. PubMed ID: 6796684 [TBL] [Abstract][Full Text] [Related]
18. [The role of chrysothiotherapy in the treatment of progressive polyarthritis]. Vojtísek O; Dostál C; Pavelka K Fysiatr Revmatol Vestn; 1984 Apr; 62(2):106-12. PubMed ID: 6430770 [No Abstract] [Full Text] [Related]
19. Cell-bound gold (CBG) in patients treated with aurothioglucose and with auranofin. A comparison of different methods of determination. van Riel PL; Gribnau FW; van de Putte LB J Rheumatol; 1983 Aug; 10(4):574-8. PubMed ID: 6413685 [TBL] [Abstract][Full Text] [Related]
20. Auranofin: 1 mg or 9 mg? The search for the appropriate dose. Calin A; Saunders D; Bennett R; Jacox R; Kaplan D; O'Brien W; Paulus HE; Roth S; Weiss T J Rheumatol Suppl; 1982; 8():146-8. PubMed ID: 6813476 [No Abstract] [Full Text] [Related] [Next] [New Search]